Making an Impact for Patients With Myeloproliferative Neoplasms (MPNs) Through Research & Awareness

At Incyte, we strive to address the challenges patients living with rare diseases face in their daily lives, but we recognize that there is more work to be done. As we join the National Organization for Rare Disorders (NORD), the European Organization for Rare Diseases (EURODIS) and other organizations in recognizing Rare Disease Day 2017, I continue to be inspired by all that has been accomplished by the community to date, as patients, caregivers, advocacy groups and other players across the healthcare ecosystem work closely together to make a positive impact on the lives of patients.

‘With research, possibilities are limitless’

Rare Disease Day puts the focus on celebrating everyday heroes, bringing together the entire community and instilling a sense of understanding, compassion and strength that make the possibilities seem boundless. This year’s Rare Disease Day theme, ‘with research, possibilities are limitless,’ is truly reflective of how we think as a company. At Incyte, we are dedicated to positively impacting the lives of patients through research and development, discovering new medicines and advancing innovative science. Our scientists come to work each day motivated by the knowledge that their efforts today have the possibility of making a difference tomorrow. I know first-hand that they are inspired by the unique stories of patients and caregivers whose lives have been changed due to research.

Bringing awareness to polycythemia vera, a rare blood cancer

Rare Disease Day fosters connectivity and support which is vital for patients living with rare diseases — such as those with myeloproliferative neoplasms (MPNs), a group of rare blood cancers — who often face a long and frustrating road to diagnosis. The reason? These conditions are often misunderstood or little is known about them.

This year, as we seek to increase awareness of MPNs — which include polycythemia vera (PV), myelofibrosis (MF) and essential thrombocythemia (ET) and affect about 200,000 people in the U.S., we are undertaking a number of educational efforts to engage the community and bring the everyday struggles and experiences of PV patients to the forefront. Visit to learn more about our programs and partnerships to showcase and connect those living with MPNs, including PV.

Get involved & nominate your 2017 MPN Heroes®

Patients, healthcare providers, caregivers, scientists and advocates work to reach an even broader audience, raise awareness and shape the MPN dialogue year-round. Our “Voices of MPN” program provides a platform to join in the conversation and share stories to raise awareness of MPNs. Since 2013, the MPN Heroes® Recognition Program, sponsored by Incyte and CURE® magazine, has recognized the people and organizations that have dedicated themselves to improving the lives of people with MPNs. Please share your voice and recognize an MPN hero by submitting a nomination at The 2017 MPN Heroes® program kicks off today and will be accepting nominations through MPN Awareness Day — September 14, 2017.

I speak on behalf of everyone at Incyte when I say that we look forward to continuing to collaborate with the entire MPN community to raise awareness, advance research, and, ultimately, translate innovative science into new therapies for patients in need.

Hervé Hoppenot, Chief Executive Officer, Incyte.

Show your support

Clapping shows how much you appreciated Hervé Hoppenot’s story.